- Home
- ANGH vs CYCC Comparison
ANGH vs CYCC Comparison
Compare ANGH & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- CYCC
- Stock Information
- Founded
- ANGH 2012
- CYCC 1992
- Country
- ANGH United Arab Emirates
- CYCC Malaysia
- Employees
- ANGH N/A
- CYCC N/A
- Industry
- ANGH Telecommunications Equipment
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- CYCC Health Care
- Exchange
- ANGH Nasdaq
- CYCC Nasdaq
- Market Cap
- ANGH 47.5M
- CYCC 47.6M
- IPO Year
- ANGH N/A
- CYCC N/A
- Fundamental
- Price
- ANGH $0.55
- CYCC $0.25
- Analyst Decision
- ANGH
- CYCC Strong Buy
- Analyst Count
- ANGH 0
- CYCC 1
- Target Price
- ANGH N/A
- CYCC $11.00
- AVG Volume (30 Days)
- ANGH 8.9K
- CYCC 7.3M
- Earning Date
- ANGH 06-30-2025
- CYCC 05-20-2025
- Dividend Yield
- ANGH N/A
- CYCC 59.13%
- EPS Growth
- ANGH N/A
- CYCC N/A
- EPS
- ANGH N/A
- CYCC N/A
- Revenue
- ANGH $78,093,405.00
- CYCC $43,000.00
- Revenue This Year
- ANGH N/A
- CYCC $137.21
- Revenue Next Year
- ANGH N/A
- CYCC N/A
- P/E Ratio
- ANGH N/A
- CYCC N/A
- Revenue Growth
- ANGH 88.72
- CYCC N/A
- 52 Week Low
- ANGH $0.42
- CYCC $0.17
- 52 Week High
- ANGH $1.15
- CYCC $3.08
- Technical
- Relative Strength Index (RSI)
- ANGH 42.39
- CYCC 47.06
- Support Level
- ANGH $0.42
- CYCC $0.28
- Resistance Level
- ANGH $0.65
- CYCC $0.37
- Average True Range (ATR)
- ANGH 0.06
- CYCC 0.07
- MACD
- ANGH -0.00
- CYCC 0.01
- Stochastic Oscillator
- ANGH 55.75
- CYCC 20.67
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.